Skip to main content

Neuralstem Rises on Publication of Alzheimer’s Stem Cell Therapy Data

Submitted by admin on
snippet
  • The neural stem cell line into APP/PS1 mice that carry genes bearing mutations associated with onset of AD in humans
  • NSI-532.IGF1 is a second-generation cell therapy candidate that is engineered to combine neural stem cells with a neuroprotective protein, IGF-1
Source
CP Wire

FDA Grants Orphan Drug Designation to Neuralstem's Treatment for Angelman Syndrome

Submitted by admin on
snippet

Neuralstem, Inc. (Nasdaq:CUR) announced on 8/9/18 that the U.S. Food and Drug Administration has granted orphan drug designation to NSI-189 for the treatment of Angelman syndrome.

Source
CP Wire